CN110522905A - 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途 - Google Patents

丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途 Download PDF

Info

Publication number
CN110522905A
CN110522905A CN201910841916.2A CN201910841916A CN110522905A CN 110522905 A CN110522905 A CN 110522905A CN 201910841916 A CN201910841916 A CN 201910841916A CN 110522905 A CN110522905 A CN 110522905A
Authority
CN
China
Prior art keywords
inhibitor
serpin
recombinant
kallikrein
serine protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910841916.2A
Other languages
English (en)
Chinese (zh)
Inventor
D·德佩尔特
C·昆丁
A·霍夫纳尼安
C·德雷松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MED DISCOVERY SA
Institut National de la Santé et de la Recherche Médicale
Original Assignee
MED DISCOVERY SA
Institut National de la Santé et de la Recherche Médicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MED DISCOVERY SA, Institut National de la Santé et de la Recherche Médicale filed Critical MED DISCOVERY SA
Publication of CN110522905A publication Critical patent/CN110522905A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Birds (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
CN201910841916.2A 2008-01-21 2009-01-21 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途 Pending CN110522905A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2238608P 2008-01-21 2008-01-21
US61/022,386 2008-01-21
US657608P 2008-01-22 2008-01-22
US61/006,576 2008-01-22
CN2009801099736A CN101977626A (zh) 2008-01-21 2009-01-21 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2009801099736A Division CN101977626A (zh) 2008-01-21 2009-01-21 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途

Publications (1)

Publication Number Publication Date
CN110522905A true CN110522905A (zh) 2019-12-03

Family

ID=40901490

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910841916.2A Pending CN110522905A (zh) 2008-01-21 2009-01-21 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途
CN2009801099736A Pending CN101977626A (zh) 2008-01-21 2009-01-21 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2009801099736A Pending CN101977626A (zh) 2008-01-21 2009-01-21 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途

Country Status (8)

Country Link
US (3) US20110130338A1 (cg-RX-API-DMAC7.html)
EP (1) EP2244728B1 (cg-RX-API-DMAC7.html)
JP (2) JP5615184B2 (cg-RX-API-DMAC7.html)
CN (2) CN110522905A (cg-RX-API-DMAC7.html)
AU (1) AU2009207394B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0906167A2 (cg-RX-API-DMAC7.html)
CA (1) CA2712512C (cg-RX-API-DMAC7.html)
WO (1) WO2009093119A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113768865A (zh) * 2020-11-04 2021-12-10 深圳前海鹰岗生物科技有限公司 一种抑制炎症因子释放治疗痛风急性发作的聚合物微针及制备方法

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009207394B2 (en) 2008-01-21 2015-01-22 Dermadis Sa Use of serine protease inhibitors in the treatment of skin diseases
CN102448473A (zh) * 2009-03-10 2012-05-09 Med发现公司 丝氨酸蛋白酶抑制剂在治疗嗜中性粒细胞减少症中的用途
EP2799471B1 (en) 2011-12-09 2019-04-24 Momentive Performance Materials Japan LLC Method for producing silicone rubber foam
CA2881431C (en) * 2012-08-08 2021-10-19 Daiichi Sankyo Company, Limited Peptide library and use thereof
KR101830926B1 (ko) * 2012-09-19 2018-02-22 맥케이 메모리얼 호스피탈 피부 노화를 방지 및/또는 개선하기 위해 사용되는 pedf-유도 폴리펩티드의 용도
KR101437408B1 (ko) 2012-11-05 2014-09-05 동아대학교 산학협력단 플라스민 및 엘라스타아제 저해 활성을 갖는 산왕거미 유래의 쿠니츠 타입 세린 프로테아제 저해 단백질 및 이를 유효성분으로 포함하는 염증 억제 및 항섬유소용해용 조성물
US10807805B2 (en) 2013-05-17 2020-10-20 Intelligrated Headquarters, Llc Robotic carton unloader
US9969573B2 (en) 2013-05-17 2018-05-15 Intelligrated Headquarters, Llc Robotic carton unloader
GB201322091D0 (en) * 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
WO2015114144A1 (en) * 2014-02-03 2015-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of netherton syndrome
AU2015223035A1 (en) * 2014-02-26 2016-09-22 Luma Therapeutics, Inc. Ultraviolet phototherapy apparatuses and methods
WO2016063991A1 (ja) * 2014-10-24 2016-04-28 株式会社資生堂 角層剥離の抑制又は亢進に起因する肌状態を改善するための美容方法及び評価方法
MA40998A (fr) 2014-11-21 2017-09-26 Ophirex Inc Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés
US10597235B2 (en) 2016-10-20 2020-03-24 Intelligrated Headquarters, Llc Carton unloader tool for jam recovery
CN106478812B (zh) * 2016-10-21 2020-11-20 沈阳药科大学 丝氨酸蛋白酶抑制剂-3及其功能、制备方法和应用
TW202313978A (zh) * 2016-11-23 2023-04-01 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
TW201841656A (zh) * 2017-04-21 2018-12-01 美商建南德克公司 Klk5拮抗劑用於治療疾病之用途
EP4740954A3 (en) * 2017-06-16 2026-08-05 Azitra, Inc. Compositions and methods for treatment of netherton syndrome with lekti expressing recombinant microbes
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
AU2019346549B2 (en) 2018-09-24 2024-09-12 Krystal Biotech, Inc. Compositions and methods for the treatment of Netherton Syndrome
AU2020349509A1 (en) 2019-09-18 2022-03-31 Genentech, Inc. Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
JP7768560B2 (ja) * 2019-11-21 2025-11-12 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 好中球エラスターゼ活性のポリペプチド阻害剤およびその使用
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
EP4114414A4 (en) * 2020-03-06 2024-03-27 The Regents of The University of Michigan SERINE PROTEASE INHIBITORS FOR SUPPRESSING OR PREVENTING ANAPHYLACTIC REACTION
JP2025502341A (ja) * 2022-01-18 2025-01-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 加齢における分解性プロテアーゼ活性を阻害する方法
JP7820193B2 (ja) * 2022-03-04 2026-02-25 株式会社ナリス化粧品 角層剥離改善剤
AU2024212280A1 (en) * 2023-01-25 2025-05-22 Quoin Pharmaceuticals, Inc. Combination treatment for netherton syndrome
CN117084936A (zh) * 2023-09-22 2023-11-21 南京盛德生物科技研究院有限公司 多萜类化合物作为激肽释放酶抑制剂在化妆品中的应用
WO2026021603A1 (zh) * 2024-07-25 2026-01-29 吉林大学第一医院 Serpina3蛋白变异体或其编码序列以及它们的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1356907A (zh) * 1999-06-18 2002-07-03 布亚纳森·乔·布拉吉 鱼丝氨酸蛋白酶及其在制药和化妆品上的应用
CN1798838A (zh) * 2003-04-04 2006-07-05 洛桑大学 一种蛋白酶的抑制剂蛋白及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079336A (en) * 1989-06-23 1992-01-07 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
US5252725A (en) * 1989-06-23 1993-10-12 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
DE4214215A1 (de) * 1992-04-30 1993-11-04 Behringwerke Ag Verwendung von inhibitoren von plasminogenaktivatoren zur behandlung von entzuendungen
AUPP508798A0 (en) * 1998-08-05 1998-08-27 Biotech Australia Pty Limited Method of treating psoriasis
US7105172B1 (en) * 1999-11-18 2006-09-12 Bolla John D Treatment of rosacea
EP1334179A2 (en) * 2000-11-14 2003-08-13 Bristol-Myers Squibb Company A human serpin secreted from lymphoid cells lsi-01
US20040097481A1 (en) * 2002-11-20 2004-05-20 Benjamin Levinson Water-soluble mesoporphyrin compounds and methods of preparation
AU2003286258B2 (en) * 2002-11-20 2006-12-21 Arriva-Prometic Inc. Composition and method for treating inflammatory diseases using protease inhibitors
WO2005117955A1 (en) * 2004-05-19 2005-12-15 Arriva Pharmaceuticals, Inc. Treatment of atopic dermatitis with unglycosylated alpha one-antitrypsin
EP1666075A1 (en) * 2004-10-04 2006-06-07 Switch Biotech Aktiengesellschaft Wound dressing compositions, especially for delivery of protease inhibitors
WO2006090282A2 (en) * 2005-02-28 2006-08-31 Universite De Lausanne Recombinant inhibitor proteins of an hk14 protease and use thereof
GB0525999D0 (en) * 2005-12-21 2006-02-01 Ares Trading Sa Novel members of the kazal family of serine protease inhibitors
BRPI0813230A2 (pt) * 2007-06-28 2014-12-23 Novartis Ag Moduladores de calicreína 7
WO2009024528A1 (en) * 2007-08-17 2009-02-26 Novartis Ag Use of cyclic depsipeptides to inhibit kallikrein 7
AU2009207394B2 (en) * 2008-01-21 2015-01-22 Dermadis Sa Use of serine protease inhibitors in the treatment of skin diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1356907A (zh) * 1999-06-18 2002-07-03 布亚纳森·乔·布拉吉 鱼丝氨酸蛋白酶及其在制药和化妆品上的应用
CN1798838A (zh) * 2003-04-04 2006-07-05 洛桑大学 一种蛋白酶的抑制剂蛋白及其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113768865A (zh) * 2020-11-04 2021-12-10 深圳前海鹰岗生物科技有限公司 一种抑制炎症因子释放治疗痛风急性发作的聚合物微针及制备方法

Also Published As

Publication number Publication date
US20110130338A1 (en) 2011-06-02
AU2009207394A1 (en) 2009-07-30
WO2009093119A3 (en) 2009-11-26
US11793864B2 (en) 2023-10-24
JP5891266B2 (ja) 2016-03-22
CA2712512C (en) 2018-08-28
WO2009093119A2 (en) 2009-07-30
AU2009207394B2 (en) 2015-01-22
JP5615184B2 (ja) 2014-10-29
BRPI0906167A2 (en) 2018-05-22
CA2712512A1 (en) 2009-07-30
EP2244728B1 (en) 2016-08-31
EP2244728A2 (en) 2010-11-03
CN101977626A (zh) 2011-02-16
US20140341881A1 (en) 2014-11-20
US20190183989A1 (en) 2019-06-20
JP2011511766A (ja) 2011-04-14
JP2014240389A (ja) 2014-12-25

Similar Documents

Publication Publication Date Title
JP5891266B2 (ja) 皮膚病の治療におけるセリンプロテアーゼ阻害剤の使用
CA2184908C (en) Human osteoclast-derived cathepsin
US5633227A (en) Secretory leukocyte protease inhibitor as an inhibitor of tryptase
CA2765423A1 (en) Casein derived protease inhibitory peptides
Guyot et al. Proteolytic susceptibility of the serine protease inhibitor trappin-2 (pre-elafin): evidence for tryptase-mediated generation of elafin
CN104159915A (zh) 牙龈蛋白酶抑制前肽
US9642898B2 (en) Use of serine protease inhibitors in the treatment of neutropenia
CA2521410C (en) Inhibitor proteins of a protease and use thereof
HK1151236A (en) Use of serine protease inhibitors in the treatment of skin diseases
US6207419B1 (en) Thrombin inhibitory agents and methods of using same
ES2604215T3 (es) Uso de inhibidores de serina proteasas en el tratamiento de enfermedades de la piel

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191203